Search results
Results from the WOW.Com Content Network
However, while dementia risk is higher in people with type 2 diabetes, it is not inevitable. Managing diabetes with medication, and making healthy lifestyle changes could significantly reduce a ...
Type 2 diabetes is associated with an increased risk of Alzheimer’s and Parkinson’s. According to a new study, certain diabetes medications may significantly reduce this risk.
Some drugs used to treat type 2 diabetes could also help lower a person’s risk of neurodegenerative diseases, such as Alzheimer’s. Image credit: martin-dm/Getty Images. This article originally ...
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.
Metformin is a first-line medication used for treatment of type 2 diabetes. It is generally prescribed at initial diagnosis in conjunction with exercise and weight loss, as opposed to the past, where it was prescribed after diet and exercise had failed.
Dementia prevention is a critical area of research, as experts want to understand what people can do to decrease dementia risk. A recent study found that more than 5 years of taking medications ...
Metformin inhibits cyclic AMP production, blocking the action of glucagon, and thereby reducing fasting glucose levels. [116] Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice, and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion. [107]